Bluebird Bio reported $2.97M in Gross Profit on Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Alnylam Pharmaceuticals ALNY:US $ 154.97M 35.33M
Amgen AMGN:US $ 5097M 208M
Biogen BIIB:US $ 2267.1M 48.2M
Biomarin Pharmaceutical BMRN:US $ 305.2M 69.43M
Bluebird Bio BLUE:US $ 2.97M 10.8M
Gilead Sciences GILD:US $ 6198M 1371M
Intercept Pharmaceuticals ICPT:US $ 92.17M 3.79M
IONIS PHARMACEUT IONS:US $ 130M 7.21M
Moderna Inc MRNA:US 4.25B 643M
Nektar Therapeutics NKTR:US $ 19.61M 1.05M
Novartis NOVN:VX 9.52B 21M
Pfizer PFE:US $ 14163M 2178M
Ptc Therapeutics PTCT:US $ 132.2M 22.89M
Regeneron Pharmaceuticals REGN:US $ 2999.6M 1445.2M
Sarepta Therapeutics SRPT:US $ 165.96M 21.39M
Seattle Genetics SGEN:US $ 341.41M 31.02M
Ultragenyx Pharmaceutical RARE:US $ 77.47M 6.37M
Vertex Pharmaceuticals VRTX:US $ 1747.65M 182.25M
YTE INCY:US $ 778.52M 105.44M